Prostate Cancer and Bone: The Elective Affinities

The onset of metastases dramatically changes the prognosis of prostate cancer patients, determining increased morbidity and a drastic fall in survival expectancy. Bone is a common site of metastases in few types of cancer, and it represents the most frequent metastatic site in prostate cancer. Of no...

Full description

Bibliographic Details
Main Authors: Nadia Rucci, Adriano Angelucci
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2014/167035
id doaj-6d59ba384d3e41f7b2a37574f641756e
record_format Article
spelling doaj-6d59ba384d3e41f7b2a37574f641756e2020-11-24T20:42:12ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/167035167035Prostate Cancer and Bone: The Elective AffinitiesNadia Rucci0Adriano Angelucci1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyThe onset of metastases dramatically changes the prognosis of prostate cancer patients, determining increased morbidity and a drastic fall in survival expectancy. Bone is a common site of metastases in few types of cancer, and it represents the most frequent metastatic site in prostate cancer. Of note, the prevalence of tumor relapse to the bone appears to be increasing over the years, likely due to a longer overall survival of prostate cancer patients. Bone tropism represents an intriguing challenge for researchers also because the preference of prostate cancer cells for the bone is the result of a sequential series of targetable molecular events. Many factors have been associated with the peculiar ability of prostate cancer cells to migrate in bone marrow and to determine mixed osteoblastic/osteolytic lesions. As anticipated by the success of current targeted therapy aimed to block bone resorption, a better understanding of molecular affinity between prostate cancer and bone microenvironment will permit us to cure bone metastasis and to improve prognosis of prostate cancer patients.http://dx.doi.org/10.1155/2014/167035
collection DOAJ
language English
format Article
sources DOAJ
author Nadia Rucci
Adriano Angelucci
spellingShingle Nadia Rucci
Adriano Angelucci
Prostate Cancer and Bone: The Elective Affinities
BioMed Research International
author_facet Nadia Rucci
Adriano Angelucci
author_sort Nadia Rucci
title Prostate Cancer and Bone: The Elective Affinities
title_short Prostate Cancer and Bone: The Elective Affinities
title_full Prostate Cancer and Bone: The Elective Affinities
title_fullStr Prostate Cancer and Bone: The Elective Affinities
title_full_unstemmed Prostate Cancer and Bone: The Elective Affinities
title_sort prostate cancer and bone: the elective affinities
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2014-01-01
description The onset of metastases dramatically changes the prognosis of prostate cancer patients, determining increased morbidity and a drastic fall in survival expectancy. Bone is a common site of metastases in few types of cancer, and it represents the most frequent metastatic site in prostate cancer. Of note, the prevalence of tumor relapse to the bone appears to be increasing over the years, likely due to a longer overall survival of prostate cancer patients. Bone tropism represents an intriguing challenge for researchers also because the preference of prostate cancer cells for the bone is the result of a sequential series of targetable molecular events. Many factors have been associated with the peculiar ability of prostate cancer cells to migrate in bone marrow and to determine mixed osteoblastic/osteolytic lesions. As anticipated by the success of current targeted therapy aimed to block bone resorption, a better understanding of molecular affinity between prostate cancer and bone microenvironment will permit us to cure bone metastasis and to improve prognosis of prostate cancer patients.
url http://dx.doi.org/10.1155/2014/167035
work_keys_str_mv AT nadiarucci prostatecancerandbonetheelectiveaffinities
AT adrianoangelucci prostatecancerandbonetheelectiveaffinities
_version_ 1716822821315805184